GoAI
Get started
PepGen Inc. logo

PepGen Inc.

PEPG

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.14

+$0.105 · +3.46%

Aug 21, 4:00 PM ET

PEPG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

33

Expensive

Momentum

50

Neutral

Sentiment

48

Mixed

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
James McArthur
Listed since
May 6, 2022
Employees
57

Market position

Day range

Current $3.14

52-week range

Current $3.14

Open
$3.09
Previous close
$3.035
Volume
672.16K
0.71× average
Average volume
950.23K
Average daily volume
Market cap
217.19M USD
Beta
1.89
Market reference 1
50-day average
$2.1631
+45.16% above average
200-day average
$3.7334
-15.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
231.35M USD
P/E (TTM)
-2.09×
P/B (TTM)
1.82×
P/S (TTM)
0×
EV / EBITDA
-2.62×
Earnings yield
-32.62%
Free cash flow yield
-29.80%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-60.81%
Return on assets
-51.55%
Return on invested capital
-56.92%

Financial health

Debt / equity
0.13×
Current ratio
11.94×
Altman Z-score
1.25
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−93.61M USD+4.22%

Net income

−89.66M USD+0.36%
Income trends across reported periods−20.05M USD−48.3M USD−76.55M USD−104.8M USDOperating income, FY2021: −27.11M USDOperating income, FY2022: −68.3M USDOperating income, FY2023: −84.77M USDOperating income, FY2024: −97.74M USDOperating income, FY2025: −93.61M USDNet income, FY2021: −27.28M USDNet income, FY2022: −69.1M USDNet income, FY2023: −78.63M USDNet income, FY2024: −89.98M USDNet income, FY2025: −89.66M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −27.11M USD. Operating income FY2022 −68.3M USD. Operating income FY2023 −84.77M USD. Operating income FY2024 −97.74M USD. Operating income FY2025 −93.61M USD. Net income FY2021 −27.28M USD. Net income FY2022 −69.1M USD. Net income FY2023 −78.63M USD. Net income FY2024 −89.98M USD. Net income FY2025 −89.66M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold1.4M USD1.51M USD1.18M USD——
Gross profit−1.4M USD−1.51M USD−1.18M USD——
Research and development71.04M USD76.48M USD68.13M USD54.08M USD23.8M USD
Selling, general, and administrative22.57M USD21.26M USD16.64M USD14.22M USD8.11M USD
Operating expenses92.22M USD96.23M USD83.58M USD68.3M USD27.11M USD
Interest income4.02M USD7.14M USD6.4M USD2.79M USD—
Depreciation and amortization1.4M USD1.51M USD1.18M USD493K USD178K USD
Operating income−93.61M USD−97.74M USD−84.77M USD−68.3M USD−27.11M USD
Net income−89.66M USD−89.98M USD−78.63M USD−69.1M USD−27.28M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings
Strong buy00%
Buy583%
Hold00%
Sell117%
Strong sell00%

Recent analyst actions

5 institutions
StifelmaintainBuy

PEPG peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PEPG

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.48M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.43M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
918.73K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
432.88K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
129.29K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
36.65K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%
Dimensional - US Core Equity Market ETF logoDimensional - US Core Equity Market ETFDFAU
Market value
32.87K
Weight
0.00%
AUM
12.79B USD
Expense ratio
0.12%
Price / 1D
$53.06+0.44%
iShares Neuroscience and Healthcare ETF logoiShares Neuroscience and Healthcare ETFIBRN
Market value
14.06K
Weight
0.18%
AUM
7.92M USD
Expense ratio
0.47%
Price / 1D
$39.62+0.61%

Continue in GoAI

Research PEPG

research.disclaimer